אסתטיקה של ולודרום ישראלי, פברואר 2022
צילום בולודרום
הולודרום, המרכז הישראלי הראשון לתחרויות אופניים באולם, הוקם לא הרחק מביתי, וביקור בו היה ברשימת ה’עשה’ שלי. ההזדמנות הראשונה לביקור נקרתה לפני בפברואר 2022, כשהוזמנתי לצלם תחרויות טנדם עבור התאחדות לספורט הנכים בארץ. בשל מזג האויר הגשום נידחו מרבית התחרויות, ונותרתי עם פעילות קצרה של טנדם יומיים לאחר המועד הראשוני שנקבע. על כך כתבתי בפוסט הקודם שלי.
אלא שביתר אותו יום המשיכו להתקיים, כרגיל, תחרויות אליפות הארץ באופניים, שנערכו באותו שבוע בולודרום. מוגבל באותו יום על ידי קריזיס קורונה משפחתי שנדרשתי אליו (ושנגמר בשלום בסופו של דבר), נשארתי לצלם עוד, ככל שהיה לי פנאי. זו היתה הזדמנות ראשונה בשבילי לחקור את האסתטיקה המיוחדת שמספק אולם הולדורום הישראלי.
הצילומים שכאן הם תוצר של אותו ביקור.
priligy dapoxetine review The following clinicians entered patients in the trial T Delozier, Centre François Baclesse, Caen 96; A Veronesi, Centro di Riferimento Oncologico, Aviano 69; E Vrdoljak, Centre of Oncology, Split 65; A Monnier, Centre Hospitalier André Boulloche, Montbeliard 64; C Coombes, Charing Cross Hospital, London 63; T Nagykalnai, Uzsoki Hospital, Budapest 57; RMH Roumen, Maxima Medisch Centrum, Veldhoven 57; B Utracka Hutka, Centre of Oncology, Gliwice 57; A Pluzanska, Medical University, Lodz 53; M Porpiglia, Ospedale Sant Anna, Torino 52; M Steiner, R Rubinov, M Leviov, Carmel Medical Centre, Haifa 48; V Semiglazov, Prof N N Petrov, Research Institute of Oncology, St Petersburg 48; J Fox, Castle Hill Hospital, Cottingham 41; JI Mayordomo, Hospital Clinico Lozano Blesa, Zaragoza 40; J Cervek, Institute of Oncology, Ljubljana 40; HP Sleeboom, Ziekenhuis Leyenburg, The Hague 39; J Jassem, Medical University of Gdansk, Gdañsk 39; CP Hinton, Princess Royal Hospital, Telford 39; TH Paulsen, RJ Guleng, Haukeland Sykehus, Bergen 38; L Fein, Centro Oncologico de Rosario, Rosario 37; N Gutulescu, Oncological Institute, Bucharest 36; J Florián, Hospital Comarcal de Barbastro, Barbastro 36; R Rosso, National Institute for Cancer Research, Genova 34; EJ Rutgers, Antoni Van Leeuwenhoek Ziekenhuis, Amsterdam 34; M Krzakowski, Oncology Centre Institute, Warsaw 33; Z Krajina, University Hospital, Osijek 32; H Siffnerova, Regional Hospital, Ceske Budejovice 32; M Pawlicki, M Sklodowska Curie Memorial Cancer Institute, Krakow 32; K Drosik, Wodewodzi Osrodek Onkologii, Opole 32; M Wagnerowa, Oncology Faculty L Pasteura, Kosice 32; M Brunt, North Staffordshire Royal Infirmary, Stoke on Trent 31; S Vukelja, Tyler Cancer Center, Tyler 31; L Mitrowic, National Cancer Research Centre, Belgrade 31; L Cataliotti, Università degli Studi, Florence 30; H Karnicka Mlodkowska, Maritime Hospital, Gdynia 30; H Bonnefoi, Hopital Cantonal Universitaire De Geneve, Geneva 29; G Tilch, District Hospital Rodewisch, Rodewisch 29; P Chollet, Centre Jean Perrin, Clermont Ferrand 29; A Patel, St Margaret s Hospital, Epping 29; C Kamby, Amtssygehuset Herlev, Herlev 28; L Giustini, Ospedale Civile, Fermo 28; H Mouridsen, Rigshospitalet, Copenhagen 27; H Roche, B De Lafontan, Institut Claudius Régaud, Toulouse 27; P Tomczak, Medical University, Poznan 27; L Petruzelka, University Hospital, Prague 26; A Lortholary, Centre Paul Papin, Angers 26; MG Pacquola, Ospedale ASL 20, Tortona 26; A Skene, Royal Bournemouth Hospital, Bournemouth 26; PF Conte, Ospedale Santa Chiara, Pisa 25; N Ghilezan, Inst Oncologic Cluj 1 Chiricuta, Cluj Napoca 25; A Stewart, Christie Hospital, Manchester 25; M Beauduin, Cetre Hôpitalier de Jolimont Lobbes, Haine St Paul 24; J Andersen, Århus Kommunehospital, Århus 24; S Vassilaros, Prolipsis Diagnostic Breast Centre, Athens 24; Dr Luigi Celio, Istituto Nazionale Tumori, Milan 24; R Bastús, Hospital Mutua de Terrassa, Terrassa 24; T Marsland, Florida Oncology Association, Orange Park 24; R Paridaens, UZ Gasthuisberg, Leuven 23; V Tzekova, Queen Joanna University Hospital, Sofia 23; W Lichtenegger, University Clinic Charité, Berlin 23; H Piersma, Martini Hospital, Groningen 23; S Jones, Texas Oncology, Dallas 23; S Holmberg, Universitetssjukhuset, Möindal 22; D Verhoeven, AZ KLINA Brasschaat 21; A Hill, St Vincents University Hospital, Dublin 21; G Porcile, Ospedale San Lazzaro, Alba 21; MF Bruno, Hospital Alvarez, Buenos Aires 20; I Chernozemski, National Oncological Centre, Sofia 20; R Coleman, Weston Park Hospital, Sheffield 20; J Jadeja, Hematology Oncology Association, Jacksonville 20; A Cohn, RMCC Colorado Springs, Colorado Springs 20; M Merlano, Ospedale S Croce, Cuneo 19; F Di Costanzo, Azienda Ospedaliera S Maria, Terni 19; A Van Bochove, Ziekenhuis de Heel, Zaandam 19; MAN Gerrits, Gooi Noord Hospital, Blaricum 19; V Malec, Oncology Institute Rossevelta, Banska Bystrica 19; A Balil, Hospital Arnau de Vilanova, Lleida 19; C Mendiola, Hospital 12 de Octubre, Madrid 19; D Dodwell, R Knox, Harrogate District Hospital, Harrogate 19; K Horgan, D Dodwell, Leeds General Infirmary, Leeds 19; T Joannides, Singleton Hospital, Swansea 19; SJ Cawthorn, Frenchay Hospital, Bristol 19; C Ghosh, Berkshire Hematology Oncology, Pittsfield 19; J Cantrell, Bruno Cancer Center, Birmingham 19; D Campos, Centro Médico Confidence, Buenos Aires 18; R Orti, Hospital Italiano de Buenos Aires, Buenos Aires 18; K Diedrich, Medical University Clinic, Lübeck 18; H Aas, Sykehuset i Vestfold, Tønsberg 18; A Barnadas, Hospital Germans Trias I Pujol, Barcelona 18; A Makris, Luton T Anderson, Texas Oncology Physicians Association, Euless 18; S Chittor, Texas Cancer Center of Mesquite, Mesquite 18; J Michel, CHU de Tivoli, La Louvière 17; P Philip, Centralsygehuset Nœstved, Nœstved 17; P Redmond, Cork University Hospital, Cork 17; WJB Mastboom, Medisch Spectrum Twente, Enschede 17; B Nordenskjöld, Universitets sjukhuset, Linköping 17; P Simmonds, Royal South Hants Hospital, Southampton 17; R J Grieve, Walsgrave Hospital, Coventry 17; A Tomova, Regional Oncology Centre, Plodiv 16; G Piot, MD Damour, Centre Médico Chirurgical Les Ormeaux, Le Havre 16; G Borea, Ospedale Cardarelli, Naples 15; G Ucci, Ospedale di Lecco, Lecco 16; E Einarsson, Höglandssjukhuset, Eksjö 16; S Nicholson, York District Hospital, York 16; EA Gardiol, Centro de Mastologia de Rosario, Rosario 15; J Kerger, Clinique Ste Elizabeth, Namur 15; W Lichtenegger, Virchow Klinikum, Berlin 15; J Schlosser, Gynaecological Practice, Chemnitz 15; M Namer, Centre Antoine Lacassagne, Nice 15; G Pinotti, Ospedale di Circolo e Fondazione Macchi, Varese 15; HJT Rutten, Catharina Ziekenhuis, Eindhoven 15; H Aas, T Iversen, Sandefjord Sykehus, Sandefjord 15; A Nejim, Airedale General Hospital, Keighley 15; A Dudov, Sofia Cancer Centre, Sofia 14; P Grundtvig, Amtssygehuset Roskilde, Roskilde 14; I Lang, National Institute of Oncology, Budapest 14; B Massidda, Policlinico Universitario San Elena Monserrato, Cagliari 14; CJH Van De Velde, Leids Universitair Medisch Centrum, Leiden 14; MH Gervasio, Instituto Portugues de Oncologia, Coimbra 14; I Tengrup, L Tennvall, Universitetssjukhuset Mas, Malmö 14; A Makris, Mount Vernon Hospital, London 14; S Goodman, Yeovil Hospital, Yeovil 14; VK Modgill, Halifax General Infirmary, Halifax 14; DA Vorobiof, Sandton Oncology Centre, Johannesburg 14; E Mickiewicz, Instituto Angel Roffo, Buenos Aires 13; J Chirgwin, Box Hill Hospital, Melbourne 13; C Focan, Les Cliniques St Joseph, Liège 13; N Albin, Centre d Oncologie Médicale, Evreux 13; AA Contu, Azienda USL 1, Sassari 13; JH Svensson, Borås lasarett, Borås 13; A C Källström, Vrinnevisjukhuset, Norrköping 13; JF Forbes, Newcastle Mater Hospital, Newcastle 12; HJ Hurtz, Practice for Internal Medicine, Haematology and Internal Oncology, Halle 12; M Tubiana Hulin, Centre René Huguenin, Saint Cloud 12; P Viens, Institut Paoli Calmettes, Marseilles 12; A Scanni, Ospedale Fatebenefratelli, Milan 12; E Arnoldi, Ospedale Civile, Trescore Balneario 12; A Bottini, Istituti Ospitalieri di Cremona, Cremona 12; V Muscat, S Brincat, Sir Paul Boffa Hospital, Malta 12; K Holmen, Sykehuset Levanger, Levanger 12; N Amaral, Hospital da Universidade de Coimbra, Coimbra 12; I Moreno, Hospital Municipal de Badalona, Barcelona 12; C Trask, A Robinson, Southend Hospital, Westcliff on Sea 12; K Mcintyre, Texas Oncology Presbyterian, Dallas 12; A Otsuka, Rocky Mountain Cancer Center, Thornton 12; B Hohaus, District Hospital Riesa, Riesa 11; V Georgoulias, University Hospital of Crete, Crete 11; S Salvagni, Azienda Ospedaliera, Parma 11; L Bidin, Ospedale Civile, Piacenza 11; F Artioli, Ospedale B Ramazzini, Carpi 11; T Engan, KP Benedikstsson, Orkdal Sanitetsforenings Sykehus, Orkanger 11; I Campbell, Waikato Hospital, Hamilton 11; V Harvey, Auckland Hospital, Auckland 11; H Zimbler, Texas Oncology Physicians Association, Dallas 11; Z Mrsic Krmpotic, Clinic for Tumours, Zagreb 11; JL Canon, Clinique Notre Dame et Reine Fabiola, Charleroi 10; PV Tchilingirov, Regional Oncology Centre, Stara Zagora 10; K Buser, FMH Innere Medizin Onkologie, Bern 10; A Bolanca, University Hospital Sestre Milosrdnice, Zagreb 10; U Reztke, Clinic of Suhl, Suhl 10; M Jouve, Institut Curie, Paris 10; G Mullins, Bon Secours Hospital, Cork 10; L Vesentini, Ospedale Sant Anna Divisione C, Torino 10; L Gallo, Ospedale Galliera, Genova 10; I Carreca, Università degli Studi, Palermo 10; PJM Bakker, Academisch Medisch Centrum, Amsterdam 10; B Börjesson, Länssjukhuset, Halmstad 10; J Hansen, Centrallasarettet, Vasteras 10; I Koza, National Cancer Institute, Bratislava 10; A Arcusa, Hospital General de Terrassa, Barcelona 10; A Inoriza, Hospital Infanta Cristina, Badajoz 10; A Pelegri, Hospital Sant Joan, Reus Tarragona 10; O Eremin, Lincoln and Louth County Hospital, Lincoln 10; MR Modiano, ACRC, Tucson 10; S Anthony, Cancer Care Northwest, Spokane 16; D Donat, Institute of Oncology, Sremska Kamenica 10; E Richardet, Hospital Italiano Córdoba, Córdoba 9; O Kochli, Kantonsspital Basel, Basel 9; P Zeißig, District Hospital Greiz, Greiz 9; G Gauch, Internal oncological Practice, Gera 9; K Aabo, Viborg Sygehus, Viborg 9; P Fumoleau, Centre René Gauducheau, Nantes 9; FLG Erdkamp, Maasland Ziekenhuis, Sittard 9; L Lovén, Central sjukhuset, Kristianstad 9; P E Jönsson, Lasarettet, Helsingborg 9; T Perren, St James University Hospital, Leeds 9; N Stuart, Gwynedd Hospital, Bangor 9; E Galindo, South Texas Cancer Center, Mcallen 9; J Chirgwin, Maroondah Hospital, Melbourne 8; JP Salmon, Centre Hôpitalier Peltzer La Tourelle, Verviers 8; N Dohollou, Polyclinique Nord Aquitaine, Bordeaux 8; R Thompson, Altnagelvin General Hospital, Londonderry 8; U Folco, Ospedale Santa Corona, Pietra ligure 8; A Rosa Bian Ospedale di Thiene, Thiene 8; M Tonato, Colozza M, Policlinico Monteluce, Perugia 8; GJ Heijmans, Streekziekenhuis Midden Twente, Hengelo 8; P Koralewski, Regional Hospital, Krakow 8; H Bång, Motala lasarett, Motala 8; A Rodriguez Lescure, Hospital General de Elche, Elche Alicante 8; M Martin, Hospital Clinico San Carlos, Madrid 8; F Neave, North Middlesex Hospital, Edmonton 8; T Howell, Withington Hospital, Manchester 8; M Savin, North Texas Regional Cancer Center, Plano 12; D Loesch, Oncology and Hematology Assoc Inc, Indianapolis 14; A Hannois, Hospital Eva Perón, Buenos Aires 7; A Mohr, Practice for Hematology and Oncology, Hamburg 7; T Laube, Henneberg Kliniken, Hildburghausen 7; S Omar, National Cancer Institute, Cairo 7; J Bonneterre V